Detalhe da pesquisa
1.
Innate immune recognition of cancer.
Annu Rev Immunol
; 33: 445-74, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25622193
2.
STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Immunity
; 41(5): 830-42, 2014 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-25517615
3.
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.
Semin Immunol
; 28(1): 54-63, 2016 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-26872631
4.
Innate immune mediators in cancer: between defense and resistance.
Immunol Rev
; 274(1): 290-306, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27782320
5.
Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.
Am J Respir Crit Care Med
; 197(9): 1164-1176, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29327939
6.
The STING pathway and the T cell-inflamed tumor microenvironment.
Trends Immunol
; 36(4): 250-6, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25758021
7.
Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.
J Immunol
; 196(7): 3191-8, 2016 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26927800
8.
Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
Adv Exp Med Biol
; 1036: 19-31, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-29275462
9.
Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression.
J Immunol
; 189(9): 4674-83, 2012 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23028051
10.
The role of complement in tumor growth.
Adv Exp Med Biol
; 772: 229-62, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24272362
11.
Heavy chains of inter alpha inhibitor (IαI) inhibit the human complement system at early stages of the cascade.
J Biol Chem
; 287(24): 20100-10, 2012 Jun 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-22528482
12.
LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager.
Front Immunol
; 13: 1008764, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36159851
13.
A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.
Clin Cancer Res
; 28(23): 5190-5201, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36166004
14.
Endogenous and pharmacologic targeting of the STING pathway in cancer immunotherapy.
Cytokine
; 77: 245-7, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26315534
15.
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.
Mol Cancer
; 9: 139, 2010 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-20529262
16.
Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack.
Cancer Immunol Immunother
; 58(11): 1771-80, 2009 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-19259664
17.
Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.
Cell Rep
; 25(11): 3074-3085.e5, 2018 12 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30540940
18.
Innate immune signaling and regulation in cancer immunotherapy.
Cell Res
; 27(1): 96-108, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27981969
19.
Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.
Adv Immunol
; 130: 75-93, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26923000
20.
The host STING pathway at the interface of cancer and immunity.
J Clin Invest
; 126(7): 2404-11, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27367184